We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
BIO-RAD LABORATORIES

Download Mobile App




Glucose Levels May Predict Pneumonia Death Risk

By LabMedica International staff writers
Posted on 18 Jun 2012
Print article
Nondiabetic patients who have high blood glucose on admission for community-acquired pneumonia (CAP) are at significantly elevated risk for death and may benefit from intensified care.

There is a strong association between diabetes and cardiovascular disease that contributes to overall mortality from CAP and infection and acute hyperglycemia, related illnesses.

At the University Hospital of Saarland (Homburg, Germany) scientists carried out a prospective multicenter study on 6,891 patients from 12 clinical centers. The study began in July 2002, and was analyzed in December 2009. The mean age of participants was 59.8 ±18.5 years and 3,805 (55.2%) were men. Overall, 324 (4.7%) participants died within 28 days, 514 (7.5%) within 90 days, and 648 (9.4%) within 180 days. Overall mortality on days 28, 90, and 180 was significantly higher in participants with diabetes than without diabetes.

Higher serum glucose levels were associated with increased mortality in all patients. Mortality within 90 days increased in a stepwise manner in those with glucose concentrations of 108-197 mg/dL, 198-251 mg/dL, and equal or greater than 252 mg/dL when compared with patients with normal serum glucose concentrations of 72-107 mg/dL. Nondiabetics with normal blood glucose levels had the lowest 90-day mortality rate of 3%, while those with hyperglycemia had a mortality rate of 10%, and patients with diabetes had the highest death rate at 14%, irrespective of glucose levels on admission.

The authors concluded that patients with increased serum glucose levels or diabetes at the time of CAP was diagnosed were at significantly increased risk of death from the disease. Oral glucose tolerance test and close glucose monitoring after discharge are necessary to diagnose overt diabetes and to prevent subacute or long-term complications. The study was published on May 29, 2012, in the British Medical Journal (BMJ).

Related Links:
University Hospital of Saarland


Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Magnetic Bead Separation Modules
MAG and HEATMAG
Complement 3 (C3) Test
GPP-100 C3 Kit
Gold Member
Fully Automated Cell Density/Viability Analyzer
BioProfile FAST CDV

Print article

Channels

Hematology

view channel
Image: The CAPILLARYS 3 DBS devices have received U.S. FDA 510(k) clearance (Photo courtesy of Sebia)

Next Generation Instrument Screens for Hemoglobin Disorders in Newborns

Hemoglobinopathies, the most widespread inherited conditions globally, affect about 7% of the population as carriers, with 2.7% of newborns being born with these conditions. The spectrum of clinical manifestations... Read more

Immunology

view channel
Image: Exosomes can be a promising biomarker for cellular rejection after organ transplant (Photo courtesy of Nicolas Primola/Shutterstock)

Diagnostic Blood Test for Cellular Rejection after Organ Transplant Could Replace Surgical Biopsies

Transplanted organs constantly face the risk of being rejected by the recipient's immune system which differentiates self from non-self using T cells and B cells. T cells are commonly associated with acute... Read more

Microbiology

view channel
Image: The ePlex system has been rebranded as the cobas eplex system (Photo courtesy of Roche)

Enhanced Rapid Syndromic Molecular Diagnostic Solution Detects Broad Range of Infectious Diseases

GenMark Diagnostics (Carlsbad, CA, USA), a member of the Roche Group (Basel, Switzerland), has rebranded its ePlex® system as the cobas eplex system. This rebranding under the globally renowned cobas name... Read more

Pathology

view channel
Image: The revolutionary autonomous blood draw technology is witnessing growing demands (Photo courtesy of Vitestro)

Robotic Blood Drawing Device to Revolutionize Sample Collection for Diagnostic Testing

Blood drawing is performed billions of times each year worldwide, playing a critical role in diagnostic procedures. Despite its importance, clinical laboratories are dealing with significant staff shortages,... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.